199 related articles for article (PubMed ID: 29474087)
1. Thiodigalactoside-Bovine Serum Albumin Conjugates as High-Potency Inhibitors of Galectin-3: An Outstanding Example of Multivalent Presentation of Small Molecule Inhibitors.
Zhang H; Laaf D; Elling L; Pieters RJ
Bioconjug Chem; 2018 Apr; 29(4):1266-1275. PubMed ID: 29474087
[TBL] [Abstract][Full Text] [Related]
2. 1H-1,2,3-triazol-1-yl thiodigalactoside derivatives as high affinity galectin-3 inhibitors.
Salameh BA; Cumpstey I; Sundin A; Leffler H; Nilsson UJ
Bioorg Med Chem; 2010 Jul; 18(14):5367-78. PubMed ID: 20538469
[TBL] [Abstract][Full Text] [Related]
3. Tailored Multivalent Neo-Glycoproteins: Synthesis, Evaluation, and Application of a Library of Galectin-3-Binding Glycan Ligands.
Laaf D; Bojarová P; Pelantová H; Křen V; Elling L
Bioconjug Chem; 2017 Nov; 28(11):2832-2840. PubMed ID: 28976746
[TBL] [Abstract][Full Text] [Related]
4. Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3.
Böcker S; Laaf D; Elling L
Biomolecules; 2015 Jul; 5(3):1671-96. PubMed ID: 26213980
[TBL] [Abstract][Full Text] [Related]
5. Investigation into the feasibility of thioditaloside as a novel scaffold for galectin-3-specific inhibitors.
Bum-Erdene K; Gagarinov IA; Collins PM; Winger M; Pearson AG; Wilson JC; Leffler H; Nilsson UJ; Grice ID; Blanchard H
Chembiochem; 2013 Jul; 14(11):1331-42. PubMed ID: 23864426
[TBL] [Abstract][Full Text] [Related]
6. Saturation Transfer Difference NMR and Molecular Docking Interaction Study of Aralkyl-Thiodigalactosides as Potential Inhibitors of the Human-Galectin-3 Protein.
Hőgye F; Farkas LB; Balogh ÁK; Szilágyi L; Alnukari S; Bajza I; Borbás A; Fehér K; Illyés TZ; Timári I
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339036
[TBL] [Abstract][Full Text] [Related]
7. A Selective Galactose-Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model.
Rajput VK; MacKinnon A; Mandal S; Collins P; Blanchard H; Leffler H; Sethi T; Schambye H; Mukhopadhyay B; Nilsson UJ
J Med Chem; 2016 Sep; 59(17):8141-7. PubMed ID: 27500311
[TBL] [Abstract][Full Text] [Related]
8. Systematic Tuning of Fluoro-galectin-3 Interactions Provides Thiodigalactoside Derivatives with Single-Digit nM Affinity and High Selectivity.
Peterson K; Kumar R; Stenström O; Verma P; Verma PR; Håkansson M; Kahl-Knutsson B; Zetterberg F; Leffler H; Akke M; Logan DT; Nilsson UJ
J Med Chem; 2018 Feb; 61(3):1164-1175. PubMed ID: 29284090
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of hydrolytically stable multivalent ligands bearing thiodigalactoside analogues for peanut lectin and human galectin-3 binding.
Cagnoni AJ; Kovensky J; Uhrig ML
J Org Chem; 2014 Jul; 79(14):6456-67. PubMed ID: 24937526
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of new thiodigalactoside-based chemical probes to label galectin-3.
van Scherpenzeel M; Moret EE; Ballell L; Liskamp RM; Nilsson UJ; Leffler H; Pieters RJ
Chembiochem; 2009 Jul; 10(10):1724-33. PubMed ID: 19492387
[TBL] [Abstract][Full Text] [Related]
11. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
[TBL] [Abstract][Full Text] [Related]
12. Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
van Hattum H; Branderhorst HM; Moret EE; Nilsson UJ; Leffler H; Pieters RJ
J Med Chem; 2013 Feb; 56(3):1350-4. PubMed ID: 23281927
[TBL] [Abstract][Full Text] [Related]
13. Efficient synthesis of a galectin inhibitor clinical candidate (TD139) using a Payne rearrangement/azidation reaction cascade.
St-Gelais J; Denavit V; Giguère D
Org Biomol Chem; 2020 May; 18(20):3903-3907. PubMed ID: 32400847
[TBL] [Abstract][Full Text] [Related]
14. Glycopolymers Decorated with 3-
Vrbata D; Filipová M; Tavares MR; Červený J; Vlachová M; Šírová M; Pelantová H; Petrásková L; Bumba L; Konefał R; Etrych T; Křen V; Chytil P; Bojarová P
J Med Chem; 2022 Mar; 65(5):3866-3878. PubMed ID: 35157467
[TBL] [Abstract][Full Text] [Related]
15. Glycomimetic inhibitors of tandem-repeat galectins: Simple and efficient.
Vrbata D; Červený J; Kulik N; Hovorková M; Balogová S; Vlachová M; Pelantová H; Křen V; Bojarová P
Bioorg Chem; 2024 Apr; 145():107231. PubMed ID: 38394919
[TBL] [Abstract][Full Text] [Related]
16. C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions.
Cumpstey I; Sundin A; Leffler H; Nilsson UJ
Angew Chem Int Ed Engl; 2005 Aug; 44(32):5110-2. PubMed ID: 16007713
[No Abstract] [Full Text] [Related]
17. Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions.
Chan YC; Lin HY; Tu Z; Kuo YH; Hsu SD; Lin CH
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382172
[TBL] [Abstract][Full Text] [Related]
18. Poly-N-Acetyllactosamine Neo-Glycoproteins as Nanomolar Ligands of Human Galectin-3: Binding Kinetics and Modeling.
Bumba L; Laaf D; Spiwok V; Elling L; Křen V; Bojarová P
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29373511
[TBL] [Abstract][Full Text] [Related]
19. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.
Ito K; Scott SA; Cutler S; Dong LF; Neuzil J; Blanchard H; Ralph SJ
Angiogenesis; 2011 Sep; 14(3):293-307. PubMed ID: 21523436
[TBL] [Abstract][Full Text] [Related]
20. Extracellular and intracellular small-molecule galectin-3 inhibitors.
Stegmayr J; Zetterberg F; Carlsson MC; Huang X; Sharma G; Kahl-Knutson B; Schambye H; Nilsson UJ; Oredsson S; Leffler H
Sci Rep; 2019 Feb; 9(1):2186. PubMed ID: 30778105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
